Medical Products Supplies Companies

94C Innovation Drive Milton Park, OX14 4RZ Abingdon, Oxfordshire
United Kingdom of Great Britain and Northern Ireland
Telephone +44 1235 442780
Fax +44 1235 442781
marketing@oxfordimmunotec.com
http://www.oxfordimmunotec.com

Product Categories

Product categories

03 Diagnostic Tests
03.07 Other diagnostics

Other diagnostics

Our products

Product category: Other diagnostics
T-SPOT®.TB
The T‑SPOT.TB test is a revolutionary in vitro diagnostic assay that measures T cells primed to Mycobacterium tuberculosis (MTB) antigens. Based on the pioneering T-SPOT technology, it was developed for diagnosing both latent TB infection and TB disease in humans. The T-SPOT.TB test sets new clinical standards of sensitivity and reliability, even in the immunocompromised. The product was licensed in the European Union in July 2004, received FDA premarket approval in July 2008. It is replacing the tuberculin skin test, bringing effective TB testing to many new patient groups where the skin test gives poor results.

This revolutionary technology has been described in a hundreds of peer-reviewed publications which highlight the tests excellent performance in a wide range of clinical and epidemiological settings (see clinical information). These studies confirm the excellent sensitivity and specificity of T‑SPOT.TB and demonstrate its utility for the diagnosis and control of TB around the world.

The test offers hope at a time when TB has re-emerged as a major global health threat. Nearly one third of the world’s population is infected with Mycobacterium Tuberculosis. Nine million people develop active disease and TB kills an estimated 2-3 million people each year (one person every 15 seconds). The huge toll of TB on human life prompted the World Health Organisation to declare TB a “global emergency” in 1993.

The T‑SPOT.TB test offers:

Unrivalled clinical performance
Simple and robust laboratory performance
Cost-effective in TB control

Unrivalled Clinical Performance

Very few false negative results (sensitivity of 98.8%)
– Reliable detection of truly infected individuals
No patient exclusions
– Can be used in HIV, very young children, screening before anti-TNF α treatment, transplant, renal dialysis, malnourished and other immunocompromised patient groups, as well as in pregnancy

Simple and Robust Laboratory Performance

Reduced repeat testing (due to low frequency of indeterminates)
Results next day
No need for patient return visit
All procedures carried out in a controlled laboratory environment

Saves Costs in TB Control

Minimises costs associated with onward transmission
Reduces unnecessary treatment & monitoring costs from false positive results
The T-SPOT.TB-test based screening strategies are significantly cost-saving when compared to TST-based TB control programmes
The use of the T-SPOT.TB test greatly reduces the number of contacts treated to prevent one TB case

To see a summary of key clinical studies, please view our T-SPOT.TB Publications Summary.

Product category: Other diagnostics
T-Cell Xtend®
The T-Cell Xtend reagent is an antibody complex that is added to blood samples in the laboratory immediately before running the T-SPOT.TB assay. The product was licenced throughout Europe in 2008 and gained FDA premarket approval in August 2010.

The T-Cell Xtend reagent allows blood samples to be processed up to 32 hours after venepuncture without affecting the accuracy of the test.

With the T-Cell Xtend reagent, the T-SPOT.TB test offers IGRA users unrivalled flexibility

Blood can be kept at room temperature for 32 hours prior to start of assay
The longest “time to lab” of any currently available IGRA
Blood samples can now be easily shipped overnight
Blood is collected in standard lithium heparin tubes
Does not require dedicated collection tubes or shaking of tubes

Product category: Other diagnostics
T-SPOT®.CMV
The T-SPOT®.CMV test is available now as a CE-marked kit in the EU, and will soon be available in the UK as a testing service from our UK Oxford Diagnostic Laboratories.

T cell immunity against CMV is a factor in controlling viral latency and susceptibility to CMV disease. CMV can affect individuals with weaknesses in their T cell response and it is therefore an important and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients. The T-SPOT.CMV test measures the strength of T cell responses to CMV specific antigens. The T-SPOT.CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV disease.

ad: contact information

About Us

Company details
Oxford Immunotec is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company’s
T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA.

ad: company